FGFR2 and colorectal carcinoma: MSI-H was detected in 6.50% (126/1938) of the continuously enrolled CRC patients in our center, and targetable mutations were detected in (30/126) of the MSI-H patients, BRAF V600E, NTRK1 and FGFR2 fusion were the most frequent targetable alterations in this group.